Drug Delivery Business

Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin

Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).
MD&M East

FDA Hits Abbott with Warning Letter Over Freestyle Libre CGMs

Abbott is facing a warning letter from FDA regarding its Freestyle Libre family of continuous glucose monitoring (CGM) devices for use in diabetes management. The agency said it received responses ...
MobiHealthNews

Abbott's Freestyle Libre system becomes first CGM to be FDA cleared for use without fingersticks

Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...
Nasdaq

Abbott Partners Epic To Integrate Libre CGM Data Into U.S. Health Record Systems

(RTTNews) - Abbott Laboratories (ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology, announced Tuesday that it has entered a first-of-its-kind agreement with ...